Johnson & Johnson (JNJ) — Q3 2026 Earnings Preview
Key Points
| Theme | Details |
|---|---|
| Guidance Raised | FY26 reported sales guidance raised to $101.1B (midpoint, +7.3% YoY); adjusted EPS to $11.68 (+8.2% YoY) |
| Consensus vs. Guidance | Consensus for Q3 2026 revenue: $25,291M; company guidance implies continued acceleration |
| Recent Actuals | Q2 2026 reported sales: $25,310M (+6.6% YoY); adjusted EPS: $2.90 (+4.7% YoY) |
| Growth Drivers | Oncology (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT), Immunology (TREMFYA, ICOTYDE), Neuroscience (SPRAVATO, CAPLYTA), MedTech (EP, Shockwave, Abiomed, OTTAVA) |
| MedTech Outlook | Cardiovascular, Surgery, and Vision remain focus areas; OTTAVA robotic system launch underway |
| Comparables | Q3 2025 reported sales: $23,993M (+6.8% YoY); Q3 2026 faces a tougher comp but is expected to accelerate |
| Watchlist for Q3 | Execution on new product launches (ICOTYDE, OTTAVA, VARIPULSE Pro), MedTech margin/volume trends, competitive intensity in EP, China VBP impact, Orthopaedics separation progress |
Q3 2026 Consensus vs. Guidance
Q3 2026 Consensus Estimates
| Metric | Consensus Estimate | YoY Growth vs. Q3 2025 |
|---|---|---|
| Revenue ($M) | $25,291 | +5.4% |
| Gross Profit Margin | 74.1% | +0.2 pp |
| Net Income ($M) | $5,986 | -10.1% |
| EPS (GAAP) | $2.07 | -2.4% |
Full-Year 2026 Company Guidance (as of July 2026)
| Metric | Guidance Range | Midpoint | YoY Growth (vs. FY25) |
|---|---|---|---|
| Reported Sales ($B) | $100.8 – $101.4 | $101.1 | +7.3% |
| Operational Sales ($B) | $100.3 – $100.9 | $100.6 | +6.8% |
| Adjusted Operational Sales* | 6.2% – 6.8% | 6.5% | |
| Adjusted EPS (diluted) | $11.60 – $11.75 | $11.68 | +8.2% |
| Adjusted Operational EPS* | $11.50 – $11.65 | $11.58 | +7.3% |
*Excludes impact of currency, acquisitions/divestitures, and special items.
Recent Quarterly Results (Reported Actuals)
Quarterly Financials ($M)
| Quarter | Revenue | YoY Growth | Net Income | EPS (GAAP) | Adjusted EPS | Notes |
|---|---|---|---|---|---|---|
| Q2 2026 | 25,310 | +6.6% | 5,534 | 2.27 | 2.90 | Guidance raised post-Q2 |
| Q1 2026 | 24,062 | +9.9% | 5,235 | 2.14 | 2.70 | |
| Q4 2025 | 24,564 | +9.1% | 5,116 | 2.10 | 2.46 | |
| Q3 2025 | 23,993 | +6.8% | 5,152 | 2.12 | 2.80 |
Segment Performance — Q2 2026
| Segment | Revenue ($M) | YoY Growth | Key Drivers/Notes |
|---|---|---|---|
| Innovative Med | 16,384 | +7.8% | DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT, TREMFYA, SPRAVATO, CAPLYTA |
| MedTech | 8,926 | +4.5% | Wound closure, biosurgery, EP, Shockwave, contact lenses, trauma |
Q3 2025 Actuals (for YoY Comparison)
| Metric | Q3 2025 Actual | YoY Growth vs. Q3 2024 |
|---|---|---|
| Revenue ($M) | $23,993 | +6.8% |
| Net Income ($M) | $5,152 | +91.2% |
| EPS (GAAP) | $2.12 | +91.0% |
| Adjusted EPS | $2.80 | +15.7% |
Most Important Factors to Watch This Quarter
| Factor | Why It Matters |
|---|---|
| Execution on New Launches | Uptake and ramp of ICOTYDE (oral IL-23), OTTAVA robotic system, VARIPULSE Pro in EP, C2 Aero in IVL |
| MedTech Growth & Margins | Cardiovascular (EP, Shockwave, Abiomed) and Surgery (OTTAVA) are key; watch for margin improvement and volume trends |
| Competitive Intensity in EP | Management notes "lingering" competition, especially OUS; watch for share stabilization or further erosion |
| China VBP Impact | Volume-based procurement in China is expected to hit EP in H2 2026 and into 2027; monitor pricing/margin impact |
| Orthopaedics Separation | Progress toward mid-2027 separation; any updates on structure (spin vs. sale) or stranded cost management |
| Operating Leverage | Management targets at least +50 bps operating margin improvement for FY26; watch for Q3 progress |
| Product Pipeline Updates | Data/approvals for new indications (e.g., ICOTYDE in PsA/IBD, RYBREVANT in head & neck/CRC, trispecifics in myeloma) |
| Macro/Geopolitical Risks | Middle East exposure, procedure volumes, ACA subsidy expiration, and global demand resilience |
Summary and Conclusions
- Q3 2026 Preview: JNJ is expected to report another quarter of solid top-line growth, with consensus revenue at $25,291M (+5.4% YoY). The company has raised full-year guidance twice in 2026, now targeting $101.1B in reported sales (+7.3% YoY) and $11.68 in adjusted EPS (+8.2% YoY).
- Key Growth Drivers: Oncology (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT), Immunology (TREMFYA, ICOTYDE), Neuroscience (SPRAVATO, CAPLYTA), and MedTech (EP, Shockwave, Abiomed, OTTAVA) are all contributing. New launches (ICOTYDE, OTTAVA, VARIPULSE Pro) are critical to sustaining momentum.
- MedTech Focus: Cardiovascular is now the largest and fastest-growing MedTech business. Surgery is expected to accelerate with OTTAVA's launch. Vision is rebounding, especially outside the U.S. Competitive intensity in EP and China VBP are near-term headwinds.
- Comparables: Q3 2025 was a strong quarter (+6.8% YoY), so Q3 2026 faces a tougher comp, but management expects acceleration in H2 2026 and into 2027.
- Margin and Cash Flow: At least +50 bps operating margin improvement is targeted for FY26. Free cash flow is guided to ~$21B for the year.
- Risks: Competitive pressure in EP, China pricing, macro/geopolitical uncertainty, and execution risk on new launches.
- Investor Focus: Watch for updates on ICOTYDE uptake, OTTAVA placements and feedback, MedTech margin trajectory, and any early signals on 2027 outlook at the December 8 Enterprise Business Review.
Guidance Table — FY26 (as of July 2026)
| Metric | Guidance Range | Midpoint | YoY Growth (vs. FY25) | Change vs. Prior Guide |
|---|---|---|---|---|
| Reported Sales ($B) | $100.8 – $101.4 | $101.1 | +7.3% | Raised from $100.8B |
| Operational Sales ($B) | $100.3 – $100.9 | $100.6 | +6.8% | Raised |
| Adjusted Operational Sales* | 6.2% – 6.8% | 6.5% | Raised | |
| Adjusted EPS (diluted) | $11.60 – $11.75 | $11.68 | +8.2% | +$0.13 |
| Adjusted Operational EPS* | $11.50 – $11.65 | $11.58 | +7.3% | +$0.18 |
What to Listen for on the Call
- ICOTYDE (oral IL-23) launch metrics: Updated patient and prescriber counts, payer coverage, and early market expansion signals.
- OTTAVA robotic system: Early customer feedback, placement pace, and timeline for broader rollout.
- MedTech margins: Progress on operating leverage, especially as portfolio shifts to higher-growth, higher-margin businesses.
- EP (Electrophysiology): Market share trends, competitive response, and timing for OMNYPULSE/ISOPULSE launches.
- Abiomed/PROTECT IV trial: Any updates on trial progress and impact on high-risk PCI utilization.
- Vision (Surgical and Contact Lenses): U.S. PureSee IOL launch traction and Asia Pac recovery.
- Orthopaedics separation: Timeline, structure, and stranded cost management.
- 2027 Outlook: Any early color on next year’s growth and margin trajectory ahead of the December 8 EBR.
Conclusion:
Johnson & Johnson enters Q3 2026 earnings with strong momentum, having raised guidance and delivered robust growth across both Innovative Medicine and MedTech. The focus will be on execution of new product launches (especially ICOTYDE and OTTAVA), MedTech margin improvement, and navigating competitive and macro headwinds. The company is coming off a tough comp but is expected to deliver another solid quarter, with investor attention turning to the sustainability of double-digit growth into the back half of the decade.
